Candel therapeutics announces positive interim data from randomized phase 2 clinical trial of can-2409 in non-metastatic pancreatic cancer

Needham, mass., april 04, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of can-2409 plus valacyclovir (prodrug), together with standard of care (soc) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (pdac). survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 society for immunotherapy (sitc) annual meeting. based on the data presented at sitc, the u.s. food and drug administration (fda) granted fast track designation to the company for can-2409 in combination with valacyclovir for the treatment of patients with pdac in december 2023.
CADL Ratings Summary
CADL Quant Ranking